Tuesday, August 4, 2026

1500th Mass for Korean Reconciliation: A Historic Step Towards Peace

The Catholic Archdiocese of Seoul celebrated its 1,500th Mass for Korean reconciliation, emphasizing peace between North and South Korea.

Is President Lee’s Approach to North Korea Undermining National Independence?

The People Power Party criticizes President Lee for remarks seen as appeasing North Korea during the March 1 Movement anniversary.

U.S. Banks Turn to AI to Boost Deposits and Combat Customer Churn

U.S. banks leverage AI for deposit retention and customer attraction, reshaping strategies through real-time analytics.

Tag: GC Cell

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Artiva to Advance NK Cell Therapy Into Phase 3 for Rheumatoid Arthritis After Positive Mid-Stage Data

GC Cell's Artiva Biotherapeutics advances NK cell therapy AlloNK to Phase 3 trials for rheumatoid arthritis after promising Phase 2 results.

GC Cell Secures Japanese Certification for the Manufacture of Specific Cell Processing Products

GC Cell receives final certification from Japan for cell processing products, validating its manufacturing and quality systems for regenerative medicine.

GC Cell Showcases Cold Chain Innovations the Spring Symposium of the Korean Society of Laboratory Medicine

GC Cell, GC Green Cross, and GC Genome showcased innovations in diagnostics at the 2023 Spring Symposium, enhancing precision medicine.

GC Cell’s CAR-NK: Revolutionizing Solid Tumor Treatment with New Patent

GC Cell has patented an immunotherapy targeting solid tumors using its CAR-NK platform, aiming for safer, cost-effective treatments.

GCCell Secures Groundbreaking Patent for Next-Gen Cell Therapy: What It Means for the Future of Immunotherapy

GC Cell has completed the registration of core technology patents for next-gen cell and gene therapies in South Korea and Japan.

GCC2005: The Breakthrough CAR-NK Therapy for T-Cell Lymphoma Unveiled at TCLF 2026

GC Cell presents promising CD5-targeting CAR-NK therapy GCC2005 for T-cell lymphoma, showing significant efficacy and safety at TCLF.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.